When Off-Label Ketamine Meets Direct-to-Consumer Telehealth: Liability Risks and Ethical Responsibilities

Area of Science:

• Mental Health
• Pharmacology
• Digital Health

Background:

• Direct-to-consumer telemedicine has expanded mental health care access, particularly with COVID-19 regulatory flexibilities.
• Ketamine is increasingly marketed online for psychiatric conditions and delivered at home via telehealth platforms, often prescribed off-label.

Purpose of the Study:

• To examine the challenges to clinical safeguards when combining off-label ketamine prescribing with on-demand telehealth delivery.
• To analyze the implications for patient safety, clinician responsibility, and liability in telehealth mental health care.

Main Methods:

• Case study approach using a wrongful death lawsuit against a telehealth ketamine provider.
• Analysis of the interplay between off-label prescribing, on-demand delivery, and clinical oversight within telehealth platforms.

Main Results:

• The combination of off-label prescribing and on-demand telehealth delivery can strain existing clinical safeguards.
• Limited oversight of many telehealth platforms places significant responsibility and liability for patient safety on clinicians.

Conclusions:

• Robust clinical relationships, monitoring, and accountability structures are essential to support responsible care in telehealth ketamine services.
• The current model necessitates enhanced support systems to ensure patient safety and manage clinician liability.